Is Bristol Myers Squibb the Best Bargain in Big Pharma?

Bristol Myers Squibb screens as inexpensive on key valuation metrics, trading at 2.5x sales, 9.4x forward earnings, and 10.3x EV/EBITDA, with one DCF model implying about 40% upside. The offset is a looming patent cliff: Eliquis and Opdivo patents expire in 2028 and together account for nearly half of revenue, while the company expects revenue to decline slightly this year. Income investors may still be attracted by a 4.3% forward dividend yield and 17 straight years of dividend increases.

Analysis

BMS screens cheap for a reason: the market is effectively pricing an earnings bridge problem, not a multiple problem. The 2028 exclusivity roll-off creates a visible air pocket in cash flow just as the company needs to fund pipeline maturation, which means the stock can remain optically undervalued for several quarters without being a compelling catalyst-driven long. The key second-order issue is that capital allocation flexibility shrinks before the headline patent cliff hits, so dividend durability becomes the real valuation anchor rather than near-term EPS growth.

The more interesting relative value is not BMS vs the sector, but BMS vs other high-yield, lower-growth pharma names with more diversified revenue decay profiles. AbbVie still carries its own concentration risk, but its growth mix is better aligned with the market’s willingness to pay for forward cash flow, while Pfizer remains a classic value trap candidate if its post-COVID reset fails to stabilize. In that context, BMS looks like a yield vehicle with a limited re-rating path unless the growth portfolio can scale fast enough to offset legacy erosion by 2027.

Catalyst timing matters: over the next 6-12 months, the stock is more likely to trade on dividend confidence, pipeline readouts, and management commentary than on absolute valuation. If growth drugs continue compounding in the high teens while legacy decay slows, the market may start to look through 2028 and reward the stock with a modest multiple expansion; if not, the stock could de-rate further as investors price in a dividend-coverage squeeze.

The consensus appears to be underestimating how much of the bull case is already embedded in the current yield. This is not a deep-value collapse candidate; it is a low-volatility income story with binary medium-term execution risk. The asymmetry is decent for income holders, but for total-return capital the better trade is owning the cleaner growth-compounders and fading the names where patent cliff math still dominates the narrative.

Key Decisions for Investors

• Avoid initiating a fresh outright long in BMY ahead of 2026 guidance season; the risk/reward is poor until the market gets evidence that growth portfolio revenues can offset legacy declines, which is a 6-12 month process.
• Relative-value long ABBV / short BMY for the next 3-6 months: both are income names, but ABBV has a clearer path to sustaining cash flow after patent-driven revenue resets, while BMY’s multiple may stay capped by the 2028 overhang.
• Sell cash-secured puts in BMY only if targeting income and willing to own into weakness; prefer 6-9 month maturities with strikes 10-15% below spot to get paid for waiting while limiting exposure to further multiple compression.
• Long-only income mandate: hold BMY as a yield sleeve position, but cap sizing below a normal defensive healthcare weight until there is proof of dividend coverage stability post-2026.
• Pair PFE vs BMY only if looking for a mean-reversion trade on sentiment: BMY is the higher-quality cash-flow story today, but PFE may offer better torque if the market starts rewarding turnaround optionality rather than penalizing patent risk.